Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Comparison of 3-to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial

Authors
Han, Jung-KyuHwang, DoyeonYang, SeokhunPark, Sang-HyeonKang, JeehoonYang, Han-MoPark, Kyung WooKang, Hyun-JaeKoo, Bon-KwonHur, Seung-HoKim, WeonKim, Seok YeonPark, Sang-HyunHan, Seung HwanKim, Sang-HyunShin, SanghoonKim, Yong HoonPark, KyungilLee, NamhoLee, Seung JinKim, Jin WonKim, Hyo-Soo
Issue Date
May-2023
Publisher
Lippincott Williams & Wilkins Ltd.
Keywords
aspirin; dual anti-platelet therapy; drug-eluting stents
Citation
Circulation, v.147, no.18, pp 1358 - 1368
Pages
11
Journal Title
Circulation
Volume
147
Number
18
Start Page
1358
End Page
1368
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22850
DOI
10.1161/CIRCULATIONAHA.123.064264
ISSN
0009-7322
1524-4539
Abstract
BACKGROUND: Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology. METHODS: We performed an open-label, randomized trial at 37 centers in South Korea. We enrolled patients undergoing percutaneous coronary intervention using the Orsiro biodegradable-polymer sirolimus-eluting stents or the Coroflex ISAR polymerfree sirolimus-eluting stents. Patients with ST-segment-elevation myocardial infarction were excluded. Patients were randomly assigned to receive either 3- to 6-month or 12-month DAPT after percutaneous coronary intervention. The choice of antiplatelet medications was at the physician's discretion. The primary outcome was a net adverse clinical event, a composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, or major bleeding, defined as Bleeding Academic Research Consortium type 3 or 5 at 12 months. The major secondary outcomes were target lesion failure, a composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization, and major bleeding. RESULTS: A total of 2013 patients (mean age, 65.7 +/- 10.5 years; 1487 males [73.9%]; 1110 [55.1%] presented with acute coronary syndrome) were randomly assigned to 3- to 6-month DAPT (n=1002) or 12-month DAPT (n=1011). The primary outcome occurred in 37 (3.7%) patients in the 3- to 6-month DAPT group and 41 (4.1%) in the 12-month DAPT group. The noninferiority of the 3- to 6-month DAPT group to the 12-month DAPT group was met (absolute risk difference, -0.4% [1-sided 95% CI, -8% to 1.1%]; P < 0.001 for noninferiority). There were no significant differences in target lesion failure (hazard ratio, 0.98 [95% CI, 0.56-1.71], P=0.94) or major bleeding (hazard ratio, 0.82 [95% CI, 0.41-1.61], P=0.56) between the 2 groups. Across various subgroups, the treatment effect of 3- to 6-month DAPT was consistent for net adverse clinical event. CONCLUSIONS: Among patients undergoing percutaneous coronary intervention using third-generation drug-eluting stents, 3to 6-month DAPT was noninferior to 12-month DAPT for net adverse clinical event. Further research is needed to generalize this finding to other populations and to determine the ideal regimen for 3- to 6-month DAPT.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Internal Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Seung Jin photo

Lee, Seung Jin
College of Medicine (Department of Internal Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE